Avitia and Colorectal Cancer Canada Advance Patient Outcomes

While colorectal cancer remains one of the most pressing health challenges, innovation and collaboration are changing the landscape in early detection and treatment. As Colorectal Cancer Awareness Month begins, Avitia is proud to stand with Colorectal Cancer Canada in the fight against this high-burden disease. Avitia is a Canadian company that’s dedicated to advancing cancer diagnostics through NGS-based, AI-driven molecular testing. Avitia’s work builds on years of genomic testing and AI technology that identifies key tumor mutations in tissue or blood specimens — including those specific to colorectal cancer. With targeted, data-driven care pathways, Avitia prioritizes patient well-being by minimizing the need for invasive treatments. Now Canadian patients have access to precision diagnostics using non-invasive liquid biopsy, which has already helped thousands of patients nationally — as well as globally . By focusing on improving access to timely and precise testing, Avitia is committed to supporting patients and healthcare providers in making informed treatment decisions.

Read all about our shared vision to help patients succeed against this preventable, treatable, and beatable disease:

‍United for Action: Avitia and Colorectal Cancer Canada Advance Patient Outcomes